Literature DB >> 29405975

A Theoretical Basis for the Efficacy of Cancer Immunotherapy and Immunogenic Tumor Dormancy: The Adaptation Model of Immunity.

Masoud H Manjili1.   

Abstract

In the past decades, a variety of strategies have been explored to cure cancer by means of immunotherapy, which is less toxic compared with chemotherapy or radiation therapy, and could establish memory for long-lasting protection against tumor recurrence. These endeavors have been successful in offering therapeutic antibodies, vaccines, or cellular immunotherapies, which resulted in prolonging survival of some cancer patients; however, complete cures have not been consistently achieved. The conception, design, and implementation of these promising immunotherapeutic strategies have been influenced by two schools of thought in immunology, which include the "self-nonself" (SNS) model and the "danger" model. Further progress in cancer immunotherapy to achieve consistent cancer cures requires an evolution in our understanding of how the immune system works. The purpose of this review is to revisit premises and limitations of the SNS and danger models based on the outcomes of cancer immunotherapies by suggesting that both models are two sides of the same coin describing how the immune response is induced against cancer. However, neither explains how the immune response succeeds or fails in eliminating the tumor. To this end, the adaptation model has been proposed to explain efficacy of the immune response for achieving cancer cure.
© 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adaptation model; Cancer immunotherapy; Danger model; Neoantigens; Tumor dormancy; Tumor immunoediting

Mesh:

Substances:

Year:  2018        PMID: 29405975     DOI: 10.1016/bs.acr.2017.11.005

Source DB:  PubMed          Journal:  Adv Cancer Res        ISSN: 0065-230X            Impact factor:   6.242


  6 in total

Review 1.  Defining the Hallmarks of Metastasis.

Authors:  Danny R Welch; Douglas R Hurst
Journal:  Cancer Res       Date:  2019-05-03       Impact factor: 12.701

Review 2.  Multifaceted functions of chronic inflammation in regulating tumor dormancy and relapse.

Authors:  Saeed H Manjili; Madison Isbell; Negar Ghochaghi; Tyler Perkinson; Masoud H Manjili
Journal:  Semin Cancer Biol       Date:  2021-03-27       Impact factor: 15.707

Review 3.  Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses.

Authors:  Xi Chen; Xiaohui Pan; Wenxin Zhang; Hongjie Guo; Shuyuan Cheng; Qiaojun He; Bo Yang; Ling Ding
Journal:  Acta Pharm Sin B       Date:  2019-09-25       Impact factor: 11.413

Review 4.  The premise of personalized immunotherapy for cancer dormancy.

Authors:  Masoud H Manjili
Journal:  Oncogene       Date:  2020-04-22       Impact factor: 9.867

5.  The adaptation model of immunity: Is the goal of central tolerance to eliminate defective T cells or self-reactive T cells?

Authors:  Masoud H Manjili
Journal:  Scand J Immunol       Date:  2022-08-10       Impact factor: 3.889

6.  Local and distant tumor dormancy during early stage breast cancer are associated with the predominance of infiltrating T effector subsets.

Authors:  Hussein F Aqbi; Cara Coleman; Melika Zarei; Saeed H Manjili; Laura Graham; Jennifer Koblinski; Chunquing Guo; Yibin Xie; Georgi Guruli; Harry D Bear; Michael O Idowu; Mehran Habibi; Xiang-Yang Wang; Masoud H Manjili
Journal:  Breast Cancer Res       Date:  2020-10-28       Impact factor: 6.466

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.